CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection FractionMichael McDonald, Amelia Yip, Sean Virani et al.|Canadian Journal of Cardiology|2021Cited by 290
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer TherapySean Virani, Lynn Straatman, Christine Simmons et al.|Canadian Journal of Cardiology|2016Cited by 234
Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology PatientsChristopher Johnson, Jeffrey Sulpher, Margot K. Davis et al.|Canadian Journal of Cardiology|2016Cited by 173
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in AmyloidosisEileen O’Meara, Bruce Sussex, Michael McDonald et al.|Canadian Journal of Cardiology|2020Cited by 121
Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac AmyloidosisNowell M. Fine, Shelley Zieroth, Margot K. Davis et al.|Canadian Journal of Cardiology|2020Cited by 112